|2.||Neoplasm Metastasis (Metastasis)
|3.||Colorectal Neoplasms (Colorectal Cancer)
|4.||Breast Neoplasms (Breast Cancer)
|5.||Rectal Neoplasms (Rectal Cancer)
|1.||Fuchs, Charles S: 63 articles (11/2015 - 03/2002)|
|2.||Slattery, Martha L: 60 articles (09/2015 - 06/2002)|
|3.||Goldberg, Richard M: 48 articles (10/2015 - 04/2002)|
|4.||Sargent, Daniel J: 48 articles (10/2015 - 04/2002)|
|5.||Potter, John D: 44 articles (12/2015 - 06/2002)|
|6.||Ogino, Shuji: 43 articles (11/2015 - 08/2005)|
|7.||Meyerhardt, Jeffrey A: 37 articles (11/2015 - 02/2003)|
|8.||Rigas, Basil: 37 articles (10/2014 - 01/2002)|
|9.||Thibodeau, Stephen N: 32 articles (12/2015 - 07/2003)|
|10.||O'Connell, Michael J: 32 articles (12/2014 - 03/2002)|
|1.||Fluorouracil (Carac)FDA LinkGeneric
11/18/2000 - "Combinations of 5-fluorouracil are most commonly used, but current trials are exploring several new drugs with proven efficacy in metastatic colon cancer for use in the adjuvant setting. "
05/01/2013 - "To investigate whether infusional high-dose 5-flurouracil (HD-FU) provides a significant improvement in recurrence-free survival (RFS) and overall survival (OS) compared with a standard bolus 5-FU regimen (Mayo Clinic) in patients with curatively resectable stage III colon cancer. "
01/01/2012 - "We found that the incorporation of 5-FU into PCL NPs (which show no cytotoxicity alone), significantly improved the drug's anticancer activity, reducing the proliferation rate of colon cancer cells by up to 40-fold when compared with the nonincorporated drug alone. "
01/01/2008 - "Our findings suggest that targeting HK II may be beneficial for patients with colon cancer treated with 5-FU."
05/01/2008 - "Considerable progress has been made in the treatment of colon cancer from the era when 5-fluorouracil was the only effective agent for this disease. "
|2.||Leucovorin (Folinic Acid)FDA Link
03/22/2001 - "The mainstay of treatment of colon cancer is 5-Fluoruracil (5-FU), which should be combined with folinic acid in case of bolus (2-4 min. injection) therapy. "
06/01/2014 - "Patients with stage IIB or III colon cancer who had undergone curative resection were randomly assigned to receive UFT (300 mg/m(2)) plus leucovorin (75 mg/day) for 6 months (control group, 4 weeks of treatment followed by a 1-week rest, five courses) or for 18 months (study group, 5 days of treatment followed by a 2-day rest, 15 courses). "
05/01/2009 - "In the present study, we explored the therapeutic potential of combined in vivo treatment in the human colon cancer cell lines COL-1, KM12C and KM20C with consecutive oral S-1 and leucovorin (LV) in 2-week therapeutic periods. "
02/01/2001 - "The International Multicenter Pooled Analysis of Colon Cancer Trials B2 study, which combined data from patients with Dukes' B colon cancer in five separate trials, failed to show a statistically significant benefit of adjuvant 5-FU/leucovorin compared with surgery alone. "
02/01/2001 - "The aim of the IMPACT 2 study was to determine whether 5-FU/leucovorin is an effective adjuvant treatment for patients with Dukes' B2 colon cancer. "
|3.||oxaliplatin (Eloxatin)FDA LinkGeneric
07/01/2009 - "CONCLUSION Adding oxaliplatin to LV5FU2 significantly improved 5-year DFS and 6-year OS in the adjuvant treatment of stage II or III colon cancer and should be considered after surgery for patients with stage III disease."
06/01/2007 - "The addition of oxaliplatin to weekly FULV significantly improved DFS in patients with stage II and III colon cancer. "
11/01/2006 - "A review of the available evidence indicated that in patients with Stage III colon cancer, oxaliplatin in combination with an infusional de Gramont schedule of 5-FU/LV (FOLFOX4) was more effective in preventing and delaying disease recurrence than infusional 5-FU/LV alone (de Gramont regimen). "
11/01/2008 - "The MOSAIC trial showed that the use of adjuvant oxaliplatin and an infusional regimen of 5-FU/LV in the treatment of stage II/III colon cancer improved disease-free survival (DFS). "
11/01/2007 - "We therefore hypothesized that blocking oncogenic signaling with a Hsp90 inhibitor would impair metastatic behavior of colon cancer cells and also improve the efficacy of oxaliplatin in vivo. "
|4.||irinotecan (Camptosar)FDA LinkGeneric
03/01/2004 - "This case suggests the efficacy of home anticancer therapy with PMC and low-dose CPT-11 for highly advanced colon cancer in terms of QOL."
07/01/2009 - "CONCLUSION Irinotecan added to LV5FU2 as adjuvant therapy did not confer a statistically significant improvement in DFS or overall survival in patients with stage III colon cancer compared with LV5FU2 alone."
08/20/2008 - "The efficacy of NGO-PEG-SN38 was far higher than that of irinotecan (CPT-11), a FDA-approved water soluble SN38 prodrug used for the treatment of colon cancer. "
06/01/2005 - "Therefore, CRAd-sCE2/CPT-11 combination therapy appears useful for more effective treatment of colon cancer."
08/01/2004 - "l-LV/5-FU/low-dose CPT-11 seems to be effective for metastatic colon cancer, and safe from the toxicity standpoint."
06/01/2015 - " to the lack of an improvement in the pathologic complete response rate, the substantial associated toxicity, and the negative phase III trials of adjuvant bevacizumab in colon cancer, this regimen will not be pursued for further study. "
06/01/2013 - "This concept also lends some support from the NSABP C-08 adjuvant trial of colon cancer which showed very substantial improvement in time-to-recurrence for the one year of bevacizumab administration, but this benefit was quickly lost once the drug was stopped. "
01/01/2011 - "Given the lack of improvement in DFS, the use of bevacizumab cannot be recommended for use in the adjuvant treatment of patients with colon cancer."
06/01/2015 - "Because of the lack of an improvement in the path-CR rate, the substantial associated toxicity, and the negative phase III trials of adjuvant bevacizumab in colon cancer, this regimen will not be pursued for further study."
03/01/2015 - "The current study aimed to evaluate whether there was a difference in the efficacy of bevacizumab for metastatic colon cancer patients according to their BMI (kg/m). "
|6.||cetuximab (Erbitux)FDA Link
02/01/2008 - "PETACC-8, a randomized, multicenter, European Phase III trial, is comparing the efficacy of cetuximab plus FOLFOX-4 with that of FOLFOX-4 alone in patients with stage III colon cancer. "
06/01/2014 - "In this small randomized subset of patients with resected stage III colon cancer, the addition of cetuximab to FOLFIRI was associated with a nonsignificant trend toward improved DFS and OS. "
05/01/2014 - "Efficacy of cetuximab in metastatic colon cancer - case report."
04/04/2012 - "Among patients with stage III resected colon cancer, the use of cetuximab with adjuvant mFOLFOX6 compared with mFOLFOX6 alone did not result in improved disease-free survival. "
01/01/2015 - "Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial."
|7.||capecitabine (Xeloda)FDA Link
04/01/2006 - "For both breast and colon cancer, capecitabine alone or in combination with other cytotoxics is safe and effective."
12/01/2003 - "Based on its improved safety profile, capecitabine has the potential to replace 5-FU/LV as standard adjuvant treatment for patients with colon cancer. "
04/01/2015 - "The safety profile of capecitabine-based adjuvant therapy in a broad patient population with colon cancer is similar to that previously documented in phase III clinical trials."
04/01/2015 - "This observational study was conducted to document the safety of capecitabine-based adjuvant therapy in patients with resected colon cancer under routine clinical conditions. "
04/01/2015 - "Observational study of adjuvant therapy with capecitabine in colon cancer."
|8.||Levamisole (Decaris)FDA Link
03/20/2005 - "Intergroup trial 0153 (Southwest Oncology Group trial 9415) was developed to compare the efficacy of continuous-infusion FU (CIFU) plus levamisole to FU/LV plus levamisole in the adjuvant treatment of high-risk Dukes' B2 and C1 or C2 colon cancer. "
11/15/1994 - "The importance of interactions between immune cells and neoplastic cells in influencing the pathogenesis of colon cancer is suggested by the clinical efficacy of levamisole, an immunostimulant, in the treatment of colon cancer and by the association of local lymphocytic infiltration with improved prognosis. "
01/01/2006 - "Levamisole (LMS) has immunomodulatory activity, stimulates the immune system of healthy, normal volunteers and has been proposed previously as a colon cancer preventive agent. "
04/01/2004 - "Colon 205 cells, a human colonic cancer cell line, were exposed to Escherichia coli LPS (1 microg/mL) in the presence of levamisole (1 microm to 1 mm). "
10/01/2003 - "The antihelminthic Levamisole (LVM) is actually used as an immunomodulator in colon cancer. "
|9.||Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
01/01/2012 - "Acetylsalicylic acid (aspirin) is highly effective for treating colon cancer patients postdiagnosis; however, the mechanisms of action of aspirin in colon cancer are not well defined. "
05/01/2014 - "Use of aspirin (which inhibits platelet function) after a colon cancer diagnosis is associated with improved overall survival. "
07/01/2010 - "Is aspirin effective for primary prevention of colon cancer?"
12/01/2005 - "[Aspirin, is it effective for prevention of colon cancer?]."
09/15/2005 - "Aspirin is also protective against colon cancer. "
10/01/2013 - "Compared with MSI-L/MSS colon cancer, patients with MSI-H colon cancer had no significant difference in 5-year disease-free and OS (72.2 vs 68.5 %, P = 0.874; 68.1 vs 71.1 %, P = 0.437). "
01/01/2009 - "In stratified analyses, CIMP-high tumours were associated with a significant reduction in colon cancer-specific mortality, regardless of both MSI and BRAF status. "
04/01/2010 - "These findings define a unique genotype-phenotype relationship between TGFBR2 and EMT that may contribute to the improved prognosis consistently observed in colon cancers with MSI."
07/01/2003 - "Colon cancer patients with MSI have a 60% improvement in survival as compared to patients without MSI. "
01/01/2015 - "The present study revealed that tumour dissemination is less likely to occur in colon cancer patients with MSI and BRAF mutation, whereas the presence of a KRAS mutation increases the likelihood of disseminated disease."
|1.||Drug Therapy (Chemotherapy)
01/01/2014 - "Mini-probe EUS is highly effective for assigning clinical stage in colon cancer and in identifying patients who may be suitable for nonsurgical treatment including neoadjuvant chemotherapy or endoscopic resection."
01/01/2012 - "It is the aim of the present randomised controlled trial to evaluate the efficacy of primary tumour resection prior to systemic chemotherapy to prolong survival in patients with newly diagnosed colon cancer who are not amenable to curative therapy. "
11/01/2014 - "Palliative resection and subsequent chemotherapy was effective for this young patient with very advanced colon cancer that had disseminated and caused obstruction."
11/01/2010 - "It is important to remember that colon cancer treatment today is multimodal and that the improvement in patients' survival in the last decades is surely linked with the improvement in chemotherapy and the advances in the agents used. "
05/01/2001 - "Despite its proven efficacy in reducing colon cancer mortality, 5-FU-based chemotherapy is not widely used among apparently eligible patients over age 65. "
11/01/2010 - "Stage III disease patients with colon cancer experienced the largest improvement in survival, most likely related to the increased administration of adjuvant chemotherapy."
02/01/2001 - "We conclude that resection alone is a highly effective treatment for T3N0 colon cancer leaving limited opportunity for adjuvant chemotherapy to significantly impact survival. "
09/01/2015 - "There is strong evidence supporting the efficacy of adjuvant chemotherapy for patients with pathologic, stage III colon cancer. "
01/01/2015 - "In this retrospective analysis, we aimed to evaluate the survival of patients with low-risk stage II colon cancer, the efficacy of adjuvant chemotherapy in high-risk stage II colon cancer patients, and prognostic factors in stage II disease. "
11/07/2014 - "Adjuvant chemotherapy significantly reduces mortality in stage III colon cancer; however, it is only marginally effective in stage II patients. "
|3.||Heterologous Transplantation (Xenotransplantation)
12/01/1995 - "The purpose of this study was to investigate the therapeutic efficacy and toxicity of 131I-labeled CC49 MoAb administered with short fractionation schedules against human colon cancer xenografts to determine the optimal treatment schedule, with the ultimate aim of applying this approach in clinical trials. "
01/01/1993 - "In biodistribution and imaging studies in athymic mice bearing LS174T human colon cancer xenografts, the radiolabelled high-affinity cB72.3m4 antibody was rapidly cleared from the blood, whereas the low-affinity cB72.3m12 antibody had slower blood clearance. "
08/01/2001 - "Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft."
06/01/1999 - "The aim of this study was, therefore, to assess the toxicity and antitumor efficacy of RIT with the alpha emitter 213Bi/213Po, as compared to the beta emitter 90Y, linked to a monovalent Fab' fragment in a human colonic cancer xenograft model in nude mice. "
09/01/2003 - "The bsMAb cleared rapidly in nude mice bearing the GW-39 human colonic cancer xenograft. "
10/01/2012 - "Laparoscopic colectomy for colon cancer has become a standard of care, with a number of publications highlighting its safety, improved postoperative recovery, and excellent oncologic outcomes. "
11/14/2007 - "Several studies suggest improved survival among patients in whom a higher number of nodes are examined after colectomy for colon cancer. "
03/01/2006 - "Laparoscopic colectomy is associated with less overall morbidity and improved survival for patients with colonic cancers. "
08/01/2005 - "It can now be said that from an oncologic standpoint, in experienced hands, laparoscopic colectomy for curable colon cancer is equivalent to conventional therapy, and it is superior to conventional operation regarding short-term outcomes. "
09/01/2004 - "The recently published results from the largest and first prospective randomized trial with sufficient statistical power have shown that laparoscopic colectomy is as effective as open colectomy in preventing recurrence and death from colon cancer. "
06/01/2013 - "We conclude that the X, G and E mixture might act by mitochondrial pathway activation of apoptosis, possibly elicited by ROS and the mixture may be effective in the chemoprevention of colon cancer."
06/01/2002 - "These findings may help to identify key targets in the early steps of colon carcinogenesis, against which drugs that would be broadly effective for chemoprevention of colon cancer could be developed."
10/01/2012 - "With the promising results of our study, the future potential of NC-loaded Fe-bLf in chemoprevention and in the treatment of human colon cancer, deserves further investigation for translational research and preclinical studies of other malignancies."
10/01/2015 - "These new and early mechanistic studies provide a causal role of ALA in colon cancer, suggesting that ALA might be a useful agent in the management or chemoprevention of colon cancer. "
07/01/2015 - "This study provides a rationale for the use of a multi-mineral approach in the chemoprevention of colon cancer and suggests that induction of CaSR may be a measure of the effectiveness of chemopreventive agents."